Company Description
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications.
The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-α’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.
It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021.
The company was incorporated in 1984 and is based in San Diego, California.
| Country | United States |
| Founded | 1984 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Chun-Hsien Tsai |
Contact Details
Address: 8880 Rio San Diego Drive, Suite 800 San Diego, California 92108 United States | |
| Phone | 858 869 2986 |
| Website | ainos.com |
Stock Details
| Ticker Symbol | AIMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001014763 |
| CUSIP Number | 00902F105 |
| ISIN Number | US00902F3038 |
| Employer ID | 75-1974352 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Chun-Hsien Tsai | Chairman of Board, President and Chief Executive Officer |
| Hsin-Liang Lee | Chief Financial Officer |
| Chih-Heng Lu | Director of Corporate Developoment |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Oct 22, 2024 | 8-K | Current Report |
| Oct 1, 2024 | 8-K | Current Report |
| Aug 21, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Aug 20, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 16, 2024 | ARS | Filing |
| Aug 16, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 15, 2024 | DEF 14A | Other definitive proxy statements |
| Aug 9, 2024 | 8-K | Current Report |
| Aug 5, 2024 | 8-K | Current Report |